Marketing content

Cornelia Pint, Founder HEROSAN

“At HEROSAN, we want dogs and cats to be fed in a way that promotes their health and protects the environment. Working alongside vets and pet owners, we have realised just how many animals suffer from allergies and intolerances. That is why we are focusing on a fully forward-looking diet based on insects and fungi. Through this commitment, we aim to reach more households in the DACH region and expand our online and partner network. If you share this vision, become an investor in HEROSAN Healthcare GmbH and help make animal-welfare-friendly pet food part of everyday life."

Cornelia Pint, Founder HEROSAN

Investment information

Type:
Bond
Subordinated:
no
Invested so far:
€791,750.00
Price per bond:
€250.00
Transaction costs:
1.50 %
Min offer:
1 Unit
Interest:
semi-annual
Repayment:
semi-annual
after 6 Months
ISIN:
AT0000A3WD68
Broker:
Oneplanetcrowd International B.V
License:
ECSPR

Why invest in HEROSAN?

Debt financing case

Animal-welfare-friendly pet nutrition. Defined growth levers. Bond financing to support scaling.

HEROSAN is an established premium provider in animal health with insect- and mushroom-based pet food lines and a strong veterinary footprint in DACH. The bond is intended to finance marketing, e‑commerce and product development, supporting the scaling of meat‑free pet nutrition in a growing European market.

01

9.0% bond with 5‑year term

The bond offers a fixed annual interest rate of 9.0% with a 5‑year duration. It is issued by HEROSAN Healthcare GmbH and the proceeds are intended to finance growth in marketing, e‑commerce and product development.

02

Established revenue base with clear growth plan

HEROSAN generated around €3 million in annual revenue in 2023–2025 and plans to grow in the coming years. Growth is expected mainly from mushroom-based dog food, insect-protein lines and a stronger e‑commerce and specialist-retail presence.

Learn more
03

Cruelty‑free, functional pet nutrition in a growing niche

HEROSAN focuses on insect- and mushroom-based pet food instead of conventional meat. The company targets the alternative-protein and sustainable pet health segments within a DACH pet food market of well over €8 billion per year.

Learn more
04

High customer satisfaction and strong vet network

Across channels such as Google, chat and social media, HEROSAN’s products achieve around 4.9 out of 5 stars. The brand is anchored in the veterinary network in Austria and Germany and is already listed with pet supply chains such as Fressnapf.

Learn more
05

Strategic shareholders support scaling and sourcing

HEROSAN is majority-owned by REPLOID Group AG, with Biogena Group and the founders as further shareholders. They contribute access to insect and plant-based raw materials, purchasing power and B2C/B2B sales expertise, supporting the planned growth strategy without eliminating normal business risks.

Learn more
06

Sustainability and SDG-focused approach

HEROSAN’s pet food uses insect protein and mushrooms instead of conventional meat, with raw materials sourced from sustainable and regional cultivation. The company’s model is aligned with SDG 12 (Responsible consumption and production) and SDG 15 (Life on land) as described in the internal IC preparation.

Learn more

Your investment made under the Regulation (EU) 2020/1503 of the European Parliament and of the Council is not protected by the deposit guarantee schemes etablished under Directive 2024/49/EU (Deposit Guarantee Schemes Directive). Your investment is also not protected by the investor compensation schemes established under Directive 97/9/EC (Investor Compensation Schemes Directive).

Invest

About HEROSAN

HEROSAN: problem, solution and market

Problem

Sensitive pets, limited choices

Many dogs and cats suffer from sensitivities, allergies and chronic digestive issues. At the same time, pet owners are becoming more conscious of health, sustainability and animal welfare. Conventional meat‑based pet food still dominates the market and often does not fully address these needs. It relies on resource‑intensive animal proteins, can be difficult to digest for sensitive animals and offers limited options for owners who want to reduce the environmental footprint of their pet’s diet.

Solution

Cruelty‑free nutrition for sensitive pets

HEROSAN offers a completely meat-free alternative for pet nutrition. The company develops and manufactures complete pet foods and dietary supplements for dogs and cats based on insect protein and fungi, which are designed for easy digestibility and daily use. The recipes do not contain conventional meat and rely on high-quality, functional ingredients that meet the needs of sensitive and allergy-prone pets.

The products are marketed in collaboration with vets and specialist partners, enabling pet owners to combine their pets’ daily feeding routine with targeted support for gut health, skin and general wellbeing. The HEROSAN ranges are available through vets, specialist pet shops and online channels, offering pet owners convenient access to sustainable, functional nutrition without having to completely overhaul their pet’s routine all at once.

Business model

Recurring revenue from premium pet nutrition

HEROSAN’s revenue comes from the sale of its own branded pet food and supplements. The company focuses on repeat purchases, as dogs and cats consume the products every day and over long periods. Prices are set at a premium level comparable to established veterinary and specialist brands, reflecting the focus on quality and functional benefits rather than volume.

Sales are built on three main channels: veterinary practices and clinics, specialist pet retailers (including existing listings with chains such as Fressnapf) and a growing share of online sales through HEROSAN’s own web shop and selected platforms. Over time, the company aims to increase the share of direct‑to‑consumer and subscription‑type purchases to stabilise revenue and improve margins, while shareholders REPLOID Group AG and Biogena support access to raw materials, systems and sales networks.

Competitors

Competitive position in a growing niche market

HEROSAN operates in the large DACH pet food market with a total volume of well over €8 billion per year. Within this market, insect‑ and mushroom‑based products still account for only a low single‑digit share, but are growing faster than conventional meat‑based segments. This creates room for specialised providers to build recognition and customer loyalty before larger corporations expand their own ranges in these areas.

HEROSAN has already established itself as a recognised brand in cruelty‑free, functional pet nutrition, with strong roots in the veterinary channel and listings in pet supply chains such as Fressnapf. The company combines its own product formulations with the sourcing and sales strengths of shareholders REPLOID Group AG and Biogena. This combination helps HEROSAN compete in a fragmented niche, while the overall pet food market in DACH continues to grow and shift towards premium and health‑oriented products.

Impact

Impact and SDG contribution

HEROSAN’s products replace conventional meat in pet food with insect protein and mushrooms from sustainable and regional cultivation. This supports more resource‑efficient use of land, water and feed, as insects require significantly fewer resources than traditional livestock and mushroom production has a comparatively low environmental footprint. By focusing on meat‑free recipes, HEROSAN contributes to more responsible consumption and production patterns in everyday pet nutrition.

HEROSAN is linked to SDG 12 (Responsible consumption and production) and SDG 15 (Life on land). The company’s model is built around circularity in insect farming, reduced dependence on conventional animal proteins and a clear focus on animal health rather than volume sales. For pet owners, this means they can choose products that aim to support their animal’s well‑being while aligning more closely with their own sustainability and animal welfare values.

Management

HEROSAN is led by a combination of founders with deep animal health know‑how and managers with experience in scaling nutrition businesses. The founding team has worked for many years with veterinary products, focusing on formulations designed for use under veterinary guidance. This work has helped build HEROSAN’s own product concepts and a strong network among veterinarians in Austria and Germany.

Cornelia Pint, Founder

Cornelia Pint

Founder

Cornelia Pint is one of the founders of HEROSAN Healthcare GmbH. She developed the formulations for HEROSAN’s own-brand products and plays a key role within the company as a specialist consultant. Her many years of experience in the field of forward-looking animal health form an important foundation for the current ranges of pet food and dietary supplements.

Daniel Taurer, Founder

Daniel Taurer

Founder

Daniel Taurer is one of the founders of HEROSAN Healthcare GmbH and is part of the core shareholder group alongside the other founder. As a member of the founding team, he contributes to the strategic development of the company and its positioning in the premium pet health and pet food market.

Dr. Philip Pauer, Shareholder representative

Philip Pauer

Shareholder representative (REPLOID Group AG)

Philip Pauer is CEO of REPLOID Group AG, HEROSAN’s majority shareholder. Through REPLOID, he supports HEROSAN in areas such as structures, sourcing and sales expansion. REPLOID’s background in circular insect farming and alternative proteins provides industrial backing for HEROSAN’s meat‑free pet nutrition strategy.

Back to top ▲

Company structure

HEROSAN uses a straightforward company structure. HEROSAN Healthcare GmbH, based in Neutillmitsch, Austria, is both the main operating company and the issuing entity for the bond. Day‑to‑day activities in the German market are supported through a dedicated subsidiary, which focuses on local sales and market development. Production itself is largely handled by specialised external manufacturers, while sourcing and sales activities benefit from the support of strategic shareholder partners.

For investors this means that funds are provided directly to HEROSAN Healthcare GmbH, which then finances operations and growth measures within the group, including the German subsidiary and the build‑up of e‑commerce, marketing and product development.

Issuer & main operating company

HEROSAN Healthcare GmbH (Austria)

Subsidiary in Germany

Supports HEROSAN’s presence in the German market through local sales and market development.

Use of funds

The bond of HEROSAN Healthcare GmbH is offered in three subscription scenarios: minimum, medium and maximum. Across all scenarios, the proceeds will be used to strengthen marketing, e-commerce, systems and product development for HEROSAN’s animal-welfare-friendly, meat-free pet nutrition range. The company’s financial planning is based on the maximum subscription scenario of €1,500,000.

Minimum scenario

Scenario I: €250,000

Core investments to establish HEROSAN’s digital and commercial foundation.

Indicative use of funds

  • 40% – Implementation of a new web shop and initial build‑up of e‑commerce.

  • 25% – Acquisition and introduction of a new ERP system.

  • 35% – Selective staff additions in sales and online marketing, especially for the new product fungoVital, plus first steps in internationalisation.

Target scenario

Scenario II: up to €750,000

Target level to fully fund HEROSAN’s planned commercial scale‑up.

Indicative use of funds

  • 58% – For initiatives as described from Scenario I (web shop, ERP, initial sales and online marketing hires, first international steps).

  • 35% – Expanded marketing on‑ and offline, including a stronger presence with veterinarians and specialist partners.

  • 7% – Increased trade fair and network activities to support listings and brand awareness in the DACH region.

Maximum scenario

Scenario III: up to €1,500,000

Maximum planned subscription level for this bond issue.

Indicative use of funds

  • 70% – For initiatives as described from Scenario I & II (commercial scale‑up, expanded marketing, network and trade fair activities).

  • 15% – Further development of existing formulations to market readiness.

  • 15% – Development of new products to expand HEROSAN’s portfolio of cruelty‑free functional pet food and supplements.

Bonus

15% discount

15% Discount*

1–9 bonds (€250–€2,250)

Invest in 1–9 bonds and enjoy 15% off your next HEROSAN online order in the HEROSAN online shop.

Valid until 31 March 2027. Shipping costs excluded.

10% discount

20% Discount*

10–27 bonds (€2,500–€6,750)

Invest in 10–27 bonds and enjoy 20% off your next HEROSAN online order in the HEROSAN online shop.

Valid until 31 March 2027. Shipping costs excluded.

30% discount

30% Discount*

28 bonds or more (from €7,000)

Invest in 28 bonds or more and enjoy 30% off your next HEROSAN online order in the HEROSAN online shop.

Valid until 31 March 2027. Shipping costs excluded.

Notes:
*The discount code will be issued to investors only if the investment project is successfully completed. It will be processed via the Invesdor platform after the successful completion of the funding round.

Only one voucher can be assigned per user profile; multiple investments will be combined.

The code entitles you to a one-time discount in the HEROSAN online shop, with the discount level based on your total investment amount. The code is valid from the date of issue until and including 31 March 2027. It cannot be combined with other promotions or vouchers.

Shipping costs vary by delivery country and are excluded from the discount.

Financial figures & growth

Please login

This content is only visible to authenticated investors of this project.

Login

-----End of marketing content-----

Security & Risks

Security

A guarantee in the amount of 200,000 Euro is provided by REPLOID Group AG as majority shareholder of the project owner.
The value of collaterals/guarantees can fluctuate, especially in the event of default, potentially resulting in diminished return. There is a risk that the collaterals/guarantees cannot be realised.

Risk summary (simplified)

Investing in growth companies through bonds is very high risk. You can lose part or all of the money you invest.

The following text is a short and strongly simplified overview of selected risks of an investment in HEROSAN.
It is not complete and does not replace the detailed description of risks in the Key Investment Information Sheet (KIIS).

Before you invest, you must read the KIIS in full and with care and check whether you can understand and bear all of the risks described there.
If there are any differences between this summary and the KIIS, only the KIIS is legally binding.

Key risk areas (short overview)

  • Business, market and management risk
    HEROSAN is in a growth phase and is not yet sustainably profitable. Demand for its premium pet products, including those with CBD and other new ingredients, may be lower than planned – for example due to higher prices, inflation or a lack of acceptance among pet owners. Strong competition, wrong decisions by management, the loss of key employees or negative media coverage can further worsen business performance. This can lead to lower revenues and, in the worst case, to you losing all of the money you have invested.
  • Regulation, supply chain, platform and operations
    HEROSAN depends on regulated products (pet food, CBD) as well as on raw materials and external manufacturers. Changes in laws, stricter requirements or delays in approvals can mean that certain products may not be sold at all or only with restrictions. Problems with suppliers or production partners (e.g. quality, capacity, long lead times) can slow growth, increase costs and reduce HEROSAN’s ability to pay interest and repay your capital. In addition, there is a risk that the crowdfunding platform or technical systems may temporarily fail or cease operations. This can cause delays in the provision of information as well as in interest and redemption payments, even though your contractual claims generally remain in place.
  • Default, return and liquidity risk
    If HEROSAN gets into financial difficulties or becomes insolvent (for example due to poor market or business development), interest and repayments may be made late, in a reduced amount or not at all. In the worst case, you may lose all of the money you have invested. There is currently no active secondary market for this bond. You may not be able to sell your investment before the end of the term, or only by accepting financial losses. In addition, inflation, taxes and – where relevant – exchange rate fluctuations can further reduce your actual return.
  • Investor rights and technology risks of electronic securities
    As a holder of the notes, you do not have any voting or participation rights in the company and no influence on how exactly HEROSAN uses the capital raised. The bond terms can also be changed by majority decisions of the other investors, even against your will (for example lower interest or a longer term). The bond is issued as an electronic security in a digital register and held in digital wallets. Technical errors, hacker attacks or failures of these systems may mean that you temporarily or, in the worst case, permanently lose access to your electronic securities.

A complete and detailed description of all risk factors can be found only in the KIIS in the documents section of this funding round.

Back to top ▲

Documents

Investment related documents

Log in for more information.

Login Sign up

Updates

Note:

In this update section you will find new, project-relevant information that we receive.

Invesdor does not conduct a separate review of information received after the start of the financing phase.

UPDATE on 22.09.2026: What sets HEROSAN apart from standard pet food? Veterinary expertise meets an 8-billion-euro market

The DACH market for pet food has an annual volume of over €8 billion and thus offers tremendous potential. HEROSAN occupies a growing niche within this market: functional nutrition for dogs and cats with allergies, intolerances, or special dietary needs.
The formulas are rated an average of 4.8 out of 5 stars and are well-established within veterinary networks in Austria and Germany. Revenue rose by 64% to €2.3 million in the first half of 2026.

A Closer Look at the Experts on the Team

Four experts with in-depth, long-standing expertise evaluate every product idea, identify relevant needs, and clearly define the functional benefits of a formulation. In this way, HEROSAN combines technical expertise with practical development - and addresses a relevant, growing need in the pet care market.

If, in addition to learning about the experts, you’d like to find out more about the ingredients and the approach behind HEROSAN products, check out the Video.

HEROSAN

Four Perspectives Behind Every Formulation

Veterinary medicine and nutritional science meet practical product development.

In-house Veterinarian
Dr. med. vet.
Amir Goharshahi
Veterinary medical
assessment
Animal Nutrition Expert
Dipl.-Tzt.
Daniel Vozicky
Nutrition expertise in
product solutions
Veterinarian & Nutrition
Mag. Barbara
Krauser
Technical development
of concepts
HEROSAN Expert
Dr. Ulrike
Marginter
Practical & external
expert perspective
Understand the need → Define the benefit → Expert-assessed product solution

UPDATE on 15.09.2026: the mission behind HEROSAN

What began as an effort to help one dog has become HEROSAN’s mission: creating a healthier and more vital future for our pets.

When the founders’ dog suffered severely from allergies in 2019, it marked the beginning of a journey that now inspires a team of more than 30 people. What started as an initial experiment has grown into a fast-growing company with a clear vision: to support the long-term health of pets through prevention and conscious nutrition.

In the video, you will learn what drives HEROSAN, why “Longevity for Pets” is at the heart of the team’s daily work, and how dogs like Buddy can gain a better quality of life as a result.

Watch the video now to discover HEROSAN’s mission.

Update on 09.09.2026: More than just capital – strategic partners strengthen HEROSAN for the next phase of growth

HEROSAN is majority-owned by REPLOID Group AG. The BIOGENA GROUP and HEROSAN’s founding team are further shareholders. This means that two established companies from different sectors – both of which are relevant to HEROSAN – hold strategic stakes in the company.

In addition to capital, REPLOID and BIOGENA contribute their experience, networks and market expertise. This supports HEROSAN in terms of reliable sourcing, scalable structures, high-quality product development and further market access.

Three companies, a complementary combination

HEROSAN combines its own brand and product expertise with that of two strategic partners, each of whom brings different but complementary strengths to the table. This creates a network of partners that strengthens the key prerequisites for the next phase of growth: procurement, product quality, scalability, trust and market access.

Brand and product foundation

HEROSAN develops functional health, nutrition and care solutions for dogs and cats. HEROSAN combines natural active ingredients and innovative protein sources with scientific expertise to provide preventive, needs-based and species-appropriate care. Its products are established in the veterinary channel and are also listed by specialist retailers, including Fressnapf.

Contributed expertiseIn-house product and brand expertise, established positioning in the pet care market
10.000+Veterinarians in the DACH region
3Brands: entoVITAL, fungoVITAL, TAMACAN

A circular economy that pays off

REPLOID offers an innovative system for the industrial recovery of regional organic residues from the food industry. The company builds and implements modular, decentralized and highly automated insect-rearing facilities known as ReFarmUnits. In these units, black soldier fly larvae convert regional residues such as whey, spent grain and pomace into high-quality proteins and fats for feed and industrial applications, as well as insect frass used to produce premium organic fertilizer. This transforms residual materials into valuable new resources.

Contributed expertiseAccess to raw materials, industrial scaling and circular economy expertise
37,9 Mio. €Revenue 2025
5,1 Mio. €Revenue in the previous year

International health brand and consumer expertise

BIOGENA is an international health company with its own production facilities in Salzburg, its own stores and PLAZAS, e-commerce operations and scientifically developed premium micronutrient products. Since April 2025, the premium micronutrient provider has also offered products and solutions for dogs under the BIOGENA PETS brand.

Contributed expertiseHealth expertise, product quality and international market access
124,9 Mio. €Revenue 2024/25
19,1 Mio. €EBITDA 2024/25

Connection for HEROSAN: from partner profile to impact

Reploid contributes

Raw materials & scaling

  • Experience with alternative protein sources
  • Expertise in the circular economy
  • Industrial scaling capabilities

benefits directly

HEROSAN

Market position &
product expertise

Biogena contributes

Quality, brand & sales

  • Science-based product development
  • Strong brand building capabilities
  • E-commerce as well as B2C & B2B sales

Together, we are building a broader foundation for growth

HEROSAN combines its own pet care brand with complementary strengths in raw materials, scaling, health, branding and sales. This combination improves the conditions for further market expansion and the implementation of its growth strategy.

What our partners say

Philip Pauer, Founder and CEO, REPLOID Group AG

“What convinced us about HEROSAN is the combination of its team, speed and clear positioning. The company has demonstrated that it does not merely develop ideas, but turns them into market-ready products and tangible sales success. This ability to execute provides an important foundation for the next phase of growth.”

Philip Pauer Founder and CEO, REPLOID Group AG

Dr. Albert Schmidbauer, Founder and CEO, Biogena GmbH & Co. KG

“HEROSAN represents a development that we are following very closely: today, pet owners expect more from pet nutrition – greater quality, greater functionality and greater responsibility. HEROSAN established a clear position in this market at an early stage and combines these ambitions with a product approach that is an excellent fit for us and BIOGENA PETS.”

Dr. Albert Schmidbauer Founder and CEO, Biogena GmbH & Co. KG

With REPLOID and BIOGENA, HEROSAN has two strategic shareholders on board who already possess substantial operational experience, market expertise and their own networks. Their investment strengthens the foundations for further developing HEROSAN as a functional and responsible pet care brand and for implementing the next stages of growth.
These partnerships create better conditions for scaling up and market expansion, but do not guarantee commercial success. HEROSAN’s development remains dependent, amongst other things, on market acceptance, operational implementation and further financing.

Invesdor is a Eurocrowd platform member.

Ausgezeichnet als Top-Innovator 2021

Winner of the Golden Bull as the best
Crowdfunding platform 2023.

ECSP lizensiert

Invesdor is licensed under the
ECSP regulation of the EU.